H Lundbeck A/S - Product Pipeline Review - Q1 2011

H Lundbeck A/S – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “H Lundbeck A/S - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- H Lundbeck A/S - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of H Lundbeck A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of H Lundbeck A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the H Lundbeck A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate H Lundbeck A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of H Lundbeck A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the H Lundbeck A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with H Lundbeck A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of H Lundbeck A/S and identify potential opportunities in those areas.

List of Tables
List of Figures
H Lundbeck A/S Snapshot
H Lundbeck A/S Overview
Key Information
Key Facts
H Lundbeck A/S – Research and Development Overview
Key Therapeutic Areas
H Lundbeck A/S – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
H Lundbeck A/S – Pipeline Products Glance
H Lundbeck A/S – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
H Lundbeck A/S Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
H Lundbeck A/S–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
H Lundbeck A/S – Drug Profiles
Onfi
Product Description
Mechanism of Action
R&D Progress
Desmoteplase
Product Description
Mechanism of Action
R&D Progress
I.V. Carbamazepine
Product Description
Mechanism of Action
R&D Progress
Lu AA21004
Product Description
Mechanism of Action
R&D Progress
Zicronapine
Product Description
Mechanism of Action
R&D Progress
Desmoteplase
Product Description
Mechanism of Action
R&D Progress
Escitalopram + Gaboxadol
Product Description
Mechanism of Action
R&D Progress
Lu AA24493
Product Description
Mechanism of Action
R&D Progress
Lu AA24530
Product Description
Mechanism of Action
R&D Progress
Lu AA39959
Product Description
Mechanism of Action
R&D Progress
Lu AE58054
Product Description
Mechanism of Action
R&D Progress
Melperone HCl
Product Description
Mechanism of Action
R&D Progress
Lu AA24493
Product Description
Mechanism of Action
R&D Progress
Lu AE04621
Product Description
Mechanism of Action
R&D Progress
KW-6356
Product Description
Mechanism of Action
R&D Progress
H Lundbeck A/S – Pipeline Analysis
H Lundbeck A/S – Pipeline Products by Therapeutic Class
H Lundbeck A/S - Pipeline Products By Target
H Lundbeck A/S – Pipeline Products by Route of Administration
H Lundbeck A/S – Pipeline Products by Molecule Type
H Lundbeck A/S – Recent Pipeline Updates
H Lundbeck A/S - Dormant Projects
H Lundbeck A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Lu AA37096
Lu AA34893
Lu AA38466
Lu AA39959
Lu AA44608
Lu AA47070
Lu-35-138
Siramesine
H Lundbeck A/S – Company Statement
H Lundbeck A/S – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 04, 2010: Lundbeck's Phase III Study Of Clobazam Meets Primary Efficacy Endpoint
May 27, 2010: Lundbeck Initiates Enrollment In Phase III program Using Lu AA21004 In Major Depression
May 25, 2010: Lundbeck Plans To Submit NDA For Clobazam For Treatment Of Lennox-Gastaut Syndrome
Apr 06, 2010: Lundbeck Initiates Phase I Clinical Studies Of Lu AE04621 For Treatment Of Parkinson's Disease
Mar 16, 2010: H. Lundbeck's Desmoteplase Enters Clinical Phase II In Japan In Ischaemic Stroke Representing Lundbeck's First Clinical Programme In Japan
Mar 04, 2010: Lundbeck And Takeda To Initiate Phase III Pivotal Clinical Trials With Lu AA21004
Mar 04, 2010: Lundbeck And Takeda To Initiate Phase III Clinical Trials With Lu AA24530
Feb 25, 2010: H. Lundbeck A/S Announces That Data From A Post hoc Analysis Using Desmoteplase In Ischaemic Stroke Presented At The International Stroke Conference
Dec 18, 2009: Zicronapine Shows Significant Positive Data In Clinical Phase II In The Treatment Of Patients With Schizophrenia - Planning For Continued Clinical Work
Nov 27, 2009: Lundbeck Initiates Clinical Phase II Trials With Lu AE58054 As Augmentation Treatment In Alzheimer's Disease
Financial Deals Landscape
H Lundbeck A/S, Deals Volume Summary, 2004 to YTD 2011
H Lundbeck A/S, Deals Summary By Region, 2004 to YTD 2011
H Lundbeck A/S, Deals Summary, 2004 to YTD 2011
H Lundbeck A/S Detailed Deal Summary
Asset Purchase
Lundbeck Acquires UK And Ireland Rights Of Nalmefene From Britannia Pharmaceuticals
Acquisition
H. Lundbeck Acquires Laboratoire Elaiapharm
H. Lundbeck Acquires LifeHealth
Lundbeck Acquires NeuronIcon
Lundbeck Acquires OVATION Pharmaceuticals
Venture Financing
LifeCycle Pharma Secures $18.95 Million In Series C Financing
Innovative Medicines Initiative Partners With H. Lundbeck And Kings College London
to-BBB technologies Enters Into Collaboration Agreement With H Lundbeck
BioAlliance Pharma Enters Into Co-Promotion Agreement With Lundbeck
Asterand Enters Into Co-Development Agreement With Lundbeck
Lundbeck Signs An Agreement With Aarhus University
Lundbeck Enters Into Co-Marketing Agreement With Myriad Genetics
Lundbeck Enters Into A Co-Development Agreement With Takeda
Lundbeck Enters Into Co-Promotion Agreement With Merck
Lundbeck And Forest Laboratories Enter Into Distribution Agreement With Alphapharm
Lundbeck Enters Into Agreement With PAION
Merck & Co Extends An Agreement With H. Lundbeck
Merck & Co. Enters Into An Agreement With H. Lundbeck
Lundbeck Terminates Its Agreement With Merck
Lundbeck Terminates Its Agreement With Cephalon
Licensing Agreements
Lundbeck Enters Into Licensing Agreement With Sun Pharmaceuticals
Lundbeck Enters Into Agreement With Neurim
Lundbeck Expands License Agreement With PAION
Pharmexa Extends Licensing Agreement With Lundbeck
Lundbeck Enters Into Licensing Agreement With Neurim Pharmaceuticals
Shasun Pharma Enters Into Licensing Agreement With Lundbeck
Lundbeck Signs Licensing Agreement With Biotie
LifeCycle Pharma Enters Into Agreement With Lundbeck
Lay Line Enters Into Licensing Agreement With Lundbeck
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
H Lundbeck A/S – Pipeline by Therapy Area and Indication, 2011
H Lundbeck A/S – Pipeline by Stage of Development, 2011
H Lundbeck A/S – Monotherapy Products in Pipeline, 2011
H Lundbeck A/S – Combination Treatment Modalities in Pipeline, 2011
H Lundbeck A/S – Filed, 2011
H Lundbeck A/S – Phase III, 2011
H Lundbeck A/S - Phase II, 2011
H Lundbeck A/S - Phase I, 2011
H Lundbeck A/S - Pipeline By Therapeutic Class, 2011
H Lundbeck A/S - Pipeline By Target, 2011
H Lundbeck A/S – Pipeline By Route of Administration, 2011
H Lundbeck A/S – Pipeline By Molecule Type, 2011
H Lundbeck A/S – Recent Pipeline Updates, 2011
H Lundbeck A/S - Dormant Developmental Projects, 2010
H Lundbeck A/S - Discontinued Pipeline Products, 2010
H Lundbeck A/S, Subsidiaries
H Lundbeck A/S, Deals Summary, 2004 to YTD 2011
H Lundbeck A/S, Deals Summary by Region, 2004 to YTD 2011
H Lundbeck A/S, Deals Summary, 2004 to YTD 2011
H Lundbeck A/S, Deals Summary, 2004 to YTD 2011

List of Figures
H Lundbeck A/S – Pipeline by Therapy Area and Indication, 2011
H Lundbeck A/S – Pipeline by Stage of Development, 2011
H Lundbeck A/S – Monotherapy Products in Pipeline, 2011
H Lundbeck A/S – Combination Treatment Modalities in Pipeline, 2011
H Lundbeck A/S – Pipeline By Therapeutic Class, 2011
H Lundbeck A/S - Pipeline By Target, 2011
H Lundbeck A/S – Pipeline By Route of Administration, 2011

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.